Cardiovascular complications of immune checkpoint inhibitors

• Egile Nagusiak: A. A. Kulievа (Egilea), E. I. Emelina (Egilea), G. E. Gendlin (Egilea), I. G. Nikitin (Egilea), S. K. Zyryanov (Egilea), S. I. Varentsov (Egilea), I. I. Zakharova (Egilea)
• Formatua: Liburua
• Argitaratua: Izdatelstvo OKI, 2020-04-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Cardiovascular toxicity of cancer therapies remains an urgent problem today. The creation of highly effect antitumor drugs also means the appearance of new adverse effects. Immune checkpoint inhibitors (ICI) is a new class of antitumor drugs that is different from traditional chemotherapeutic and ta...